A Nano-Strategy for Advanced Triple-Negative Breast Cancer Therapy by Regulating Intratumoral Microbiota
Nano Letters · 16.04.2025 · 25 (15) · 6134-6144
DOI: 10.1021/acs.nanolett.5c00298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 03.04.2025. Verfasst von Jifan Gao und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. Ch…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Doxycycline, Microbiota. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: ?333 Project? of Jiangsu Province, Six Talent Peaks Project in Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Intratumoral microbiota have been identified as a component of the tumor microenvironment that regulates the metastatic behavior of tumors. They serve not only as indicators of tumor pathology but also as potential drug targets in cancer therapy. Herein, a multifunctional nanoplatform (DD@FEL) is prepared by combining antibiotic doxycycline (DOXY) that can combat intratumoral microbiota and the chemotherapeutic drug doxorubicin (DOX) in ergosterol-originated liposome. Specially, ergosterol is utilized as a substitute for cholesterol in liposomes to exert pharmacological activity. Mechanistically, DD@FEL leveraged DOXY to inhibit cancer metastasis based on the regulation of intratumoral microbiota, which synergizes with the chemotherapeutic effect of DOX, eventually inhibiting the progression of triple-negative breast cancer (TNBC). Verified both in vitro and in vivo, DD@FEL effectively exerts a cytotoxic effect on TNBC cells, delays the growth of primary TNBC, and attenuates the development of its lung metastasis, providing a promising therapeutic strategy to control both orthotopic and metastatic TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China.
- NMPA Key Laboratory for Research and Evaluation of Cosmetics, China Pharmaceutical University, Nanjing 211198, P. R. China.
- Institute of Pharmacology and Toxicology, University Hospital, University of Bonn, Bonn 53127, Germany.
ORCID-Profile: Wei Wang
Förderung
- ?333 Project? of Jiangsu Province
- Six Talent Peaks Project in Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Gao, J., Tang, L., Fu, C., Cao, Y., Liu, H., Yin, Y., Li, Z., Zhu, Y., Shu, W., Zhang, Y., Ru, X., & Wang, W. (2025). A Nano-Strategy for Advanced Triple-Negative Breast Cancer Therapy by Regulating Intratumoral Microbiota. Nano Letters, 25(15), 6134-6144. https://doi.org/10.1021/acs.nanolett.5c00298
Vancouver
Gao J, Tang L, Fu C, Cao Y, Liu H, Yin Y, et al. A Nano-Strategy for Advanced Triple-Negative Breast Cancer Therapy by Regulating Intratumoral Microbiota. Nano Letters. 2025;25(15):6134-6144. doi:10.1021/acs.nanolett.5c00298
BibTeX
@article{Gao2025,
author = {Gao, Jifan and Tang, Lu and Fu, Cong and Cao, Yuqi and Liu, Hening and Yin, Yue and Li, Zixuan and Zhu, Yuanbo and Shu, Weijie and Zhang, Yi and Ru, Xinrong and Wang, Wei},
title = {A Nano-Strategy for Advanced Triple-Negative Breast Cancer Therapy by Regulating Intratumoral Microbiota},
journal = {Nano Letters},
year = {2025},
volume = {25},
number = {15},
pages = {6134--6144},
doi = {10.1021/acs.nanolett.5c00298}
}
EUVIMED